How has Catalyst Pharmaceutical's operating lease liabilities changed year-over-year?

Catalyst Pharmaceutical's operating lease liabilities decreased by 9.3% year-over-year, from -$97K to -$106K.

What is the long-term trend for Catalyst Pharmaceutical's operating lease liabilities?

Over 3 years (2022 to 2025), Catalyst Pharmaceutical's operating lease liabilities has grown at a 9.3% compound annual growth rate (CAGR), from -$307K to -$401K.

Catalyst Pharmaceutical CPRX Operating lease liabilities

Operating lease liabilities at other companies

Edgewise Therapeutics, Inc.EWTX

——

Scholar RockSRRK

——

Mirum Pharmaceuticals, Inc.MIRM

——

BridgeBio PharmaBBIO

——

TG TherapeuticsTGTX

——

Arrowhead ResearchARWR

——

Other financials

Income statement

See full

Revenue$149.4M+5.6%

Gross profit$134.9M+9.2%

Operating income$73.2M+15.6%

Net income$63.7M+12.3%

EPS (diluted)$0.50+11.1%

Balance sheet

See full

Cash & equivalents$755.9M+30.2%

Total debt$2.7M-13.3%

Total equity$1.0B+27.5%

Total assets$1.1B+26.3%

Cash flow

See full

Operating cash flow$59.6M-0.8%

CapEx$27.0K—

Free cash flow$59.6M-0.8%

Valuation

See full

Market cap$3.84B+2.7%

Enterprise value$3.09B-4.1%

P/E17.4×-1.6×

P/S6.4×-0.6×

Profitability

See full

Gross margin86%-0.2pp

Operating margin44.8%+1.6pp

Net margin37.1%+0.2pp

FCF margin34.9%-15.2pp

Returns & leverage

See full

Return on equity24.5%-4.6pp

Debt / equity0×0.0×

Current ratio7.1×+1.0×

Where this comes from

Reported directly by Catalyst Pharmaceutical in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: Catalyst Pharmaceutical’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Catalyst Pharmaceutical's operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Catalyst Pharmaceutical's operating lease liabilities?: Catalyst Pharmaceutical (CPRX) reported operating lease liabilities of -$106K in Q1 2026.
How has Catalyst Pharmaceutical's operating lease liabilities changed year-over-year?: Catalyst Pharmaceutical's operating lease liabilities decreased by 9.3% year-over-year, from -$97K to -$106K.
What is the long-term trend for Catalyst Pharmaceutical's operating lease liabilities?: Over 3 years (2022 to 2025), Catalyst Pharmaceutical's operating lease liabilities has grown at a 9.3% compound annual growth rate (CAGR), from -$307K to -$401K.